Cytek Biosciences Q3 revenue rises 2% on US growth
Overview
Cell analysis solutions firm's Q3 revenue rose 2% yr/yr
Company's Q3 gross margin improved by nearly 600 basis points yr/yr
Company maintained midpoint of 2026 revenue guidance, narrowing the range
Outlook
Cytek Biosciences sees 2026 revenue between $208 mln and $211 mln
Company expects a strong finish to 2026 and continued market share gains
Result Drivers
US GROWTH AND HIGH-END INSTRUMENT DEMAND - Co said Q3 revenue growth was led by the U.S. market, with strong demand for high-end instruments and continued growth in service
RECURRING REVENUE - Co said recurring revenue from service and reagents increased, making up a larger share of total revenue
GROSS MARGIN EXPANSION - Co reported higher gross margin, citing improved product and service mix
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Slight Beat* | $53.23 mln | $52.80 mln (2 Analysts) |
Q3 Net Loss | $6.10 mln | ||
Q3 Adjusted EBITDA | $711,000 | ||
Q3 Pretax Loss | $6.91 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Reuters Recommended Reads
Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook
Nov 3 - Revvity Q3 revenue beats estimates, raises FY guidance
Nov 3 - SOPHiA GENETICS Q3 revenue rises on US market strength
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)